ID   KPCA_RAT                Reviewed;         672 AA.
AC   P05696;
DT   01-NOV-1988, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-OCT-2024, entry version 223.
DE   RecName: Full=Protein kinase C alpha type;
DE            Short=PKC-A;
DE            Short=PKC-alpha;
DE            EC=2.7.11.13 {ECO:0000250|UniProtKB:P17252};
GN   Name=Prkca; Synonyms=Pkca;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   PubMed=3387228; DOI=10.1093/nar/16.11.5199;
RA   Ono Y., Fujii T., Igarashi K., Kikkawa U., Ogita K., Nishizuka Y.;
RT   "Nucleotide sequences of cDNAs for alpha and gamma subspecies of rat brain
RT   protein kinase C.";
RL   Nucleic Acids Res. 16:5199-5200(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   PubMed=3666147; DOI=10.1016/0014-5793(87)80291-0;
RA   Kikkawa U., Ogita K., Ono Y., Asaoka Y., Shearman M.S., Fujii T., Ase K.,
RA   Sekiguchi K., Igarashi K., Nishizuka Y.;
RT   "The common structure and activities of four subspecies of rat brain
RT   protein kinase C family.";
RL   FEBS Lett. 223:212-216(1987).
RN   [3]
RP   INTERACTION WITH CAVIN2.
RX   PubMed=9566962; DOI=10.1083/jcb.141.3.601;
RA   Mineo C., Ying Y.-S., Chapline C., Jaken S., Anderson R.G.W.;
RT   "Targeting of protein kinase Calpha to caveolae.";
RL   J. Cell Biol. 141:601-610(1998).
RN   [4]
RP   FUNCTION IN CELL CYCLE ARREST.
RX   PubMed=11076962; DOI=10.1083/jcb.151.4.763;
RA   Frey M.R., Clark J.A., Leontieva O., Uronis J.M., Black A.R., Black J.D.;
RT   "Protein kinase C signaling mediates a program of cell cycle withdrawal in
RT   the intestinal epithelium.";
RL   J. Cell Biol. 151:763-778(2000).
RN   [5]
RP   FUNCTION IN CARDIAC HYPERTROPHY.
RX   PubMed=11864993; DOI=10.1083/jcb.200108062;
RA   Braz J.C., Bueno O.F., De Windt L.J., Molkentin J.D.;
RT   "PKC alpha regulates the hypertrophic growth of cardiomyocytes through
RT   extracellular signal-regulated kinase1/2 (ERK1/2).";
RL   J. Cell Biol. 156:905-919(2002).
RN   [6]
RP   FUNCTION IN HEART FAILURE, AND SUBCELLULAR LOCATION.
RX   PubMed=15271671; DOI=10.1152/ajpheart.00171.2004;
RA   Vijayan K., Szotek E.L., Martin J.L., Samarel A.M.;
RT   "Protein kinase C-alpha-induced hypertrophy of neonatal rat ventricular
RT   myocytes.";
RL   Am. J. Physiol. 287:H2777-H2789(2004).
RN   [7]
RP   REVIEW.
RX   PubMed=3045562; DOI=10.1038/334661a0;
RA   Nishizuka Y.;
RT   "The molecular heterogeneity of protein kinase C and its implications for
RT   cellular regulation.";
RL   Nature 334:661-665(1988).
RN   [8]
RP   FUNCTION.
RX   PubMed=19176525; DOI=10.1074/jbc.m808719200;
RA   Yamasaki T., Takahashi A., Pan J., Yamaguchi N., Yokoyama K.K.;
RT   "Phosphorylation of activation transcription factor-2 at serine 121 by
RT   protein kinase c controls c-Jun-mediated activation of transcription.";
RL   J. Biol. Chem. 284:8567-8581(2009).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-226; SER-319 AND THR-638, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 155-293 IN COMPLEX WITH
RP   PHOSPHATIDYLSERINE AND CALCIUM.
RX   PubMed=10562545; DOI=10.1093/emboj/18.22.6329;
RA   Verdaguer N., Corbalan-Garcia S., Ochoa W.F., Fita I.,
RA   Gomez-Fernandez J.C.;
RT   "Ca(2+) bridges the C2 membrane-binding domain of protein kinase Calpha
RT   directly to phosphatidylserine.";
RL   EMBO J. 18:6329-6338(1999).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 156-292 IN COMPLEX WITH
RP   PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE AND CALCIUM, MUTAGENESIS OF TYR-195;
RP   LYS-209; LYS-211 AND TRP-245, AND SUBCELLULAR LOCATION.
RX   PubMed=19346474; DOI=10.1073/pnas.0813099106;
RA   Guerrero-Valero M., Ferrer-Orta C., Querol-Audi J., Marin-Vicente C.,
RA   Fita I., Gomez-Fernandez J.C., Verdaguer N., Corbalan-Garcia S.;
RT   "Structural and mechanistic insights into the association of PKCalpha-C2
RT   domain to PtdIns(4,5)P2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:6603-6607(2009).
CC   -!- FUNCTION: Calcium-activated, phospholipid- and diacylglycerol (DAG)-
CC       dependent serine/threonine-protein kinase that is involved in positive
CC       and negative regulation of cell proliferation, apoptosis,
CC       differentiation, migration and adhesion, cardiac hypertrophy,
CC       angiogenesis, platelet function and inflammation, by directly
CC       phosphorylating targets such as RAF1, BCL2, CSPG4, TNNT2/CTNT, or
CC       activating signaling cascades involving MAPK1/3 (ERK1/2) and RAP1GAP.
CC       Depending on the cell type, is involved in cell proliferation and cell
CC       growth arrest by positive and negative regulation of the cell cycle.
CC       Can promote cell growth by phosphorylating and activating RAF1, which
CC       mediates the activation of the MAPK/ERK signaling cascade, and/or by
CC       up-regulating CDKN1A, which facilitates active cyclin-dependent kinase
CC       (CDK) complex formation. In cells stimulated by the phorbol ester PMA,
CC       can trigger a cell cycle arrest program which is associated with the
CC       accumulation of the hyper-phosphorylated growth-suppressive form of RB1
CC       and induction of the CDK inhibitors CDKN1A and CDKN1B. Depending on the
CC       cell type, exhibits anti-apoptotic function and protects cells from
CC       apoptosis by suppressing the p53/TP53-mediated activation of IGFBP3, or
CC       mediates anti-apoptotic action by phosphorylating BCL2. During
CC       macrophage differentiation induced by macrophage colony-stimulating
CC       factor (CSF1), is translocated to the nucleus and is associated with
CC       macrophage development. After wounding, translocates from focal
CC       contacts to lamellipodia and participates in the modulation of
CC       desmosomal adhesion. Plays a role in cell motility by phosphorylating
CC       CSPG4, which induces association of CSPG4 with extensive lamellipodia
CC       at the cell periphery and polarization of the cell accompanied by
CC       increases in cell motility. During chemokine-induced CD4(+) T cell
CC       migration, phosphorylates CDC42-guanine exchange factor DOCK8 resulting
CC       in its dissociation from LRCH1 and the activation of GTPase CDC42 (By
CC       similarity). Negatively regulates myocardial contractility and
CC       positively regulates angiogenesis, platelet aggregation and thrombus
CC       formation in arteries. Mediates hypertrophic growth of neonatal
CC       cardiomyocytes, in part through a MAPK1/3 (ERK1/2)-dependent signaling
CC       pathway, and upon PMA treatment, is required to induce cardiomyocyte
CC       hypertrophy up to heart failure and death, by increasing protein
CC       synthesis, protein-DNA ratio and cell surface area. Regulates
CC       cardiomyocyte function by phosphorylating cardiac troponin T
CC       (TNNT2/CTNT), which induces significant reduction in actomyosin ATPase
CC       activity, myofilament calcium sensitivity and myocardial contractility.
CC       In angiogenesis, is required for full endothelial cell migration,
CC       adhesion to vitronectin (VTN), and vascular endothelial growth factor A
CC       (VEGFA)-dependent regulation of kinase activation and vascular tube
CC       formation. Involved in the stabilization of VEGFA mRNA at post-
CC       transcriptional level and mediates VEGFA-induced cell proliferation. In
CC       the regulation of calcium-induced platelet aggregation, mediates
CC       signals from the CD36/GP4 receptor for granule release, and activates
CC       the integrin heterodimer ITGA2B-ITGB3 through the RAP1GAP pathway for
CC       adhesion. During response to lipopolysaccharides (LPS), may regulate
CC       selective LPS-induced macrophage functions involved in host defense and
CC       inflammation. But in some inflammatory responses, may negatively
CC       regulate NF-kappa-B-induced genes, through IL1A-dependent induction of
CC       NF-kappa-B inhibitor alpha (NFKBIA/IKBA). Upon stimulation with 12-O-
CC       tetradecanoylphorbol-13-acetate (TPA), phosphorylates EIF4G1, which
CC       modulates EIF4G1 binding to MKNK1 and may be involved in the regulation
CC       of EIF4E phosphorylation. Phosphorylates KIT, leading to inhibition of
CC       KIT activity. Phosphorylates ATF2 which promotes cooperation between
CC       ATF2 and JUN, activating transcription (By similarity). Phosphorylates
CC       SOCS2 at 'Ser-52' facilitating its ubiquitination and proteasomal
CC       degradation (By similarity). Phosphorylates KLHL3 in response to
CC       angiotensin II signaling, decreasing the interaction between KLHL3 and
CC       WNK4 (By similarity). Phosphorylates and activates LRRK1, which
CC       phosphorylates RAB proteins involved in intracellular trafficking (By
CC       similarity). {ECO:0000250|UniProtKB:P17252,
CC       ECO:0000250|UniProtKB:P20444, ECO:0000269|PubMed:11076962,
CC       ECO:0000269|PubMed:11864993, ECO:0000269|PubMed:15271671,
CC       ECO:0000269|PubMed:19176525}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.13;
CC         Evidence={ECO:0000250|UniProtKB:P17252};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.13; Evidence={ECO:0000250|UniProtKB:P17252};
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU00041,
CC         ECO:0000269|PubMed:10562545, ECO:0000269|PubMed:19346474};
CC       Note=Binds 3 Ca(2+) ions per subunit. The ions are bound to the C2
CC       domain. {ECO:0000269|PubMed:10562545, ECO:0000269|PubMed:19346474};
CC   -!- ACTIVITY REGULATION: Classical (or conventional) PKCs (PRKCA, PRKCB and
CC       PRKCG) are activated by calcium and diacylglycerol (DAG) in the
CC       presence of phosphatidylserine. Three specific sites; Thr-497
CC       (activation loop of the kinase domain), Thr-638 (turn motif) and Ser-
CC       657 (hydrophobic region), need to be phosphorylated for its full
CC       activation.
CC   -!- SUBUNIT: Interacts with ADAP1/CENTA1, CSPG4 and PRKCABP (By
CC       similarity). Binds to CAVIN2 in the presence of phosphatidylserine
CC       (PubMed:9566962). Interacts with PICK1 (via PDZ domain) (By
CC       similarity). Interacts with TRIM41 (By similarity). Recruited in a
CC       circadian manner into a nuclear complex which also includes BMAL1 and
CC       RACK1 (By similarity). Interacts with PARD3 (By similarity). Interacts
CC       with SOCS2 (By similarity). {ECO:0000250|UniProtKB:P17252,
CC       ECO:0000250|UniProtKB:P20444, ECO:0000269|PubMed:9566962}.
CC   -!- INTERACTION:
CC       P05696; P34901: Sdc4; NbExp=3; IntAct=EBI-935801, EBI-1173182;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15271671}. Cell
CC       membrane {ECO:0000269|PubMed:15271671, ECO:0000269|PubMed:19346474};
CC       Peripheral membrane protein {ECO:0000305|PubMed:15271671}.
CC       Mitochondrion membrane {ECO:0000250|UniProtKB:P17252}; Peripheral
CC       membrane protein {ECO:0000250|UniProtKB:P17252}. Nucleus
CC       {ECO:0000269|PubMed:15271671}. Note=Translocated to the nucleus upon
CC       treatment with PMA or IGF1. {ECO:0000269|PubMed:15271671}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. PKC subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X07286; CAA30266.1; -; mRNA.
DR   PIR; S02248; KIRTC.
DR   PDB; 1DSY; X-ray; 2.60 A; A=155-293.
DR   PDB; 2NCE; NMR; -; A=155-293.
DR   PDB; 3GPE; X-ray; 2.00 A; A=156-292.
DR   PDB; 3RDJ; X-ray; 1.90 A; A=156-292.
DR   PDB; 3TWY; X-ray; 1.50 A; A=156-292.
DR   PDB; 4L1L; X-ray; 1.60 A; A=155-293.
DR   PDB; 5W4S; NMR; -; A=155-293.
DR   PDBsum; 1DSY; -.
DR   PDBsum; 2NCE; -.
DR   PDBsum; 3GPE; -.
DR   PDBsum; 3RDJ; -.
DR   PDBsum; 3TWY; -.
DR   PDBsum; 4L1L; -.
DR   PDBsum; 5W4S; -.
DR   AlphaFoldDB; P05696; -.
DR   BMRB; P05696; -.
DR   SMR; P05696; -.
DR   CORUM; P05696; -.
DR   IntAct; P05696; 9.
DR   MINT; P05696; -.
DR   STRING; 10116.ENSRNOP00000004699; -.
DR   BindingDB; P05696; -.
DR   ChEMBL; CHEMBL2855; -.
DR   DrugCentral; P05696; -.
DR   GlyGen; P05696; 6 sites, 1 O-linked glycan (6 sites).
DR   iPTMnet; P05696; -.
DR   PhosphoSitePlus; P05696; -.
DR   SwissPalm; P05696; -.
DR   jPOST; P05696; -.
DR   PaxDb; 10116-ENSRNOP00000004699; -.
DR   Ensembl; ENSRNOT00000004699.9; ENSRNOP00000004699.8; ENSRNOG00000003491.9.
DR   Ensembl; ENSRNOT00055050566; ENSRNOP00055041646; ENSRNOG00055029138.
DR   Ensembl; ENSRNOT00060023763; ENSRNOP00060018914; ENSRNOG00060013871.
DR   Ensembl; ENSRNOT00065032081; ENSRNOP00065025598; ENSRNOG00065019003.
DR   AGR; RGD:3395; -.
DR   RGD; 3395; Prkca.
DR   eggNOG; KOG0696; Eukaryota.
DR   GeneTree; ENSGT00940000156104; -.
DR   InParanoid; P05696; -.
DR   PhylomeDB; P05696; -.
DR   BRENDA; 2.7.11.13; 5301.
DR   Reactome; R-RNO-111933; Calmodulin induced events.
DR   Reactome; R-RNO-114516; Disinhibition of SNARE formation.
DR   Reactome; R-RNO-1250196; SHC1 events in ERBB2 signaling.
DR   Reactome; R-RNO-1433557; Signaling by SCF-KIT.
DR   Reactome; R-RNO-1433559; Regulation of KIT signaling.
DR   Reactome; R-RNO-2179392; EGFR Transactivation by Gastrin.
DR   Reactome; R-RNO-3000170; Syndecan interactions.
DR   Reactome; R-RNO-399997; Acetylcholine regulates insulin secretion.
DR   Reactome; R-RNO-416993; Trafficking of GluR2-containing AMPA receptors.
DR   Reactome; R-RNO-4419969; Depolymerization of the Nuclear Lamina.
DR   Reactome; R-RNO-450520; HuR (ELAVL1) binds and stabilizes mRNA.
DR   Reactome; R-RNO-5099900; WNT5A-dependent internalization of FZD4.
DR   Reactome; R-RNO-5218921; VEGFR2 mediated cell proliferation.
DR   Reactome; R-RNO-5668599; RHO GTPases Activate NADPH Oxidases.
DR   Reactome; R-RNO-76005; Response to elevated platelet cytosolic Ca2+.
DR   Reactome; R-RNO-8853659; RET signaling.
DR   EvolutionaryTrace; P05696; -.
DR   PRO; PR:P05696; -.
DR   Proteomes; UP000002494; Chromosome 10.
DR   GO; GO:0035866; C:alphav-beta3 integrin-PKCalpha complex; ISO:RGD.
DR   GO; GO:0045177; C:apical part of cell; ISO:RGD.
DR   GO; GO:0030424; C:axon; ISO:RGD.
DR   GO; GO:0044305; C:calyx of Held; ISO:RGD.
DR   GO; GO:0036064; C:ciliary basal body; ISO:RGD.
DR   GO; GO:0120199; C:cone photoreceptor outer segment; ISO:RGD.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0030425; C:dendrite; ISO:RGD.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISO:RGD.
DR   GO; GO:0014704; C:intercalated disc; ISO:RGD.
DR   GO; GO:0016020; C:membrane; ISO:RGD.
DR   GO; GO:0031966; C:mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; ISO:RGD.
DR   GO; GO:0043025; C:neuronal cell body; ISO:RGD.
DR   GO; GO:0005634; C:nucleus; ISO:RGD.
DR   GO; GO:1990917; C:ooplasm; ISO:RGD.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; ISO:RGD.
DR   GO; GO:0098793; C:presynapse; ISO:RGD.
DR   GO; GO:0099523; C:presynaptic cytosol; ISO:RGD.
DR   GO; GO:0032991; C:protein-containing complex; IDA:RGD.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004698; F:calcium,diacylglycerol-dependent serine/threonine kinase activity; IDA:RGD.
DR   GO; GO:0004697; F:diacylglycerol-dependent serine/threonine kinase activity; IDA:RGD.
DR   GO; GO:0019899; F:enzyme binding; ISO:RGD.
DR   GO; GO:0035403; F:histone H3T6 kinase activity; ISO:RGD.
DR   GO; GO:0005178; F:integrin binding; ISO:RGD.
DR   GO; GO:0008289; F:lipid binding; ISO:RGD.
DR   GO; GO:0004672; F:protein kinase activity; ISO:RGD.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; ISO:RGD.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW.
DR   GO; GO:0008283; P:cell population proliferation; ISO:RGD.
DR   GO; GO:0071322; P:cellular response to carbohydrate stimulus; ISO:RGD.
DR   GO; GO:0021955; P:central nervous system neuron axonogenesis; IMP:RGD.
DR   GO; GO:0002062; P:chondrocyte differentiation; ISO:RGD.
DR   GO; GO:0002159; P:desmosome assembly; ISO:RGD.
DR   GO; GO:0045184; P:establishment of protein localization; TAS:UniProtKB.
DR   GO; GO:0050930; P:induction of positive chemotaxis; ISO:RGD.
DR   GO; GO:0006874; P:intracellular calcium ion homeostasis; ISO:RGD.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:RGD.
DR   GO; GO:0097193; P:intrinsic apoptotic signaling pathway; ISO:RGD.
DR   GO; GO:0007611; P:learning or memory; IMP:RGD.
DR   GO; GO:0046716; P:muscle cell cellular homeostasis; ISO:RGD.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; ISO:RGD.
DR   GO; GO:0034351; P:negative regulation of glial cell apoptotic process; ISS:UniProtKB.
DR   GO; GO:0046325; P:negative regulation of glucose import; ISO:RGD.
DR   GO; GO:0046627; P:negative regulation of insulin receptor signaling pathway; ISO:RGD.
DR   GO; GO:0043409; P:negative regulation of MAPK cascade; ISO:RGD.
DR   GO; GO:0001933; P:negative regulation of protein phosphorylation; ISO:RGD.
DR   GO; GO:0017148; P:negative regulation of translation; IMP:RGD.
DR   GO; GO:0030593; P:neutrophil chemotaxis; ISO:RGD.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; IMP:ARUK-UCL.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; ISS:UniProtKB.
DR   GO; GO:0110063; P:positive regulation of angiotensin-activated signaling pathway; ISO:RGD.
DR   GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; ISO:RGD.
DR   GO; GO:0045780; P:positive regulation of bone resorption; ISO:RGD.
DR   GO; GO:0010613; P:positive regulation of cardiac muscle hypertrophy; IDA:UniProtKB.
DR   GO; GO:0045785; P:positive regulation of cell adhesion; ISS:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; ISS:UniProtKB.
DR   GO; GO:2000707; P:positive regulation of dense core granule biogenesis; ISS:UniProtKB.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; ISS:UniProtKB.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; ISS:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:0045921; P:positive regulation of exocytosis; IMP:RGD.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; ISO:RGD.
DR   GO; GO:0031666; P:positive regulation of lipopolysaccharide-mediated signaling pathway; ISS:UniProtKB.
DR   GO; GO:0045651; P:positive regulation of macrophage differentiation; ISS:UniProtKB.
DR   GO; GO:0045931; P:positive regulation of mitotic cell cycle; ISS:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; ISO:RGD.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IMP:RGD.
DR   GO; GO:0051965; P:positive regulation of synapse assembly; IMP:RGD.
DR   GO; GO:0043687; P:post-translational protein modification; ISO:RGD.
DR   GO; GO:0099171; P:presynaptic modulation of chemical synaptic transmission; ISO:RGD.
DR   GO; GO:0006937; P:regulation of muscle contraction; ISO:RGD.
DR   GO; GO:0050730; P:regulation of peptidyl-tyrosine phosphorylation; ISO:RGD.
DR   GO; GO:0090330; P:regulation of platelet aggregation; ISS:UniProtKB.
DR   GO; GO:0048259; P:regulation of receptor-mediated endocytosis; IMP:RGD.
DR   GO; GO:0047484; P:regulation of response to osmotic stress; ISO:RGD.
DR   GO; GO:2000300; P:regulation of synaptic vesicle exocytosis; ISO:RGD.
DR   GO; GO:0002026; P:regulation of the force of heart contraction; ISO:RGD.
DR   GO; GO:0051412; P:response to corticosterone; IEP:RGD.
DR   GO; GO:0032355; P:response to estradiol; IMP:RGD.
DR   GO; GO:0045471; P:response to ethanol; IMP:RGD.
DR   GO; GO:0070555; P:response to interleukin-1; ISO:RGD.
DR   GO; GO:0009612; P:response to mechanical stimulus; IEP:RGD.
DR   GO; GO:0014070; P:response to organic cyclic compound; IEP:RGD.
DR   GO; GO:0043434; P:response to peptide hormone; IEP:RGD.
DR   GO; GO:0000302; P:response to reactive oxygen species; IMP:RGD.
DR   GO; GO:0009636; P:response to toxic substance; IEP:RGD.
DR   GO; GO:0048863; P:stem cell differentiation; ISO:RGD.
DR   CDD; cd20833; C1_cPKC_rpt1; 1.
DR   CDD; cd20836; C1_cPKC_rpt2; 1.
DR   CDD; cd04026; C2_PKC_alpha_gamma; 1.
DR   CDD; cd05615; STKc_cPKC_alpha; 1.
DR   Gene3D; 3.30.60.20; -; 2.
DR   Gene3D; 2.60.40.150; C2 domain; 1.
DR   Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR046349; C1-like_sf.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR035892; C2_domain_sf.
DR   InterPro; IPR034663; cPKC_alpha.
DR   InterPro; IPR020454; DAG/PE-bd.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR002219; PE/DAG-bd.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR014375; Protein_kinase_C_a/b/g.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   PANTHER; PTHR24351:SF242; PROTEIN KINASE C; 1.
DR   PANTHER; PTHR24351; RIBOSOMAL PROTEIN S6 KINASE; 1.
DR   Pfam; PF00130; C1_1; 2.
DR   Pfam; PF00168; C2; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   PIRSF; PIRSF000550; PKC_alpha; 1.
DR   PRINTS; PR00360; C2DOMAIN.
DR   PRINTS; PR00008; DAGPEDOMAIN.
DR   SMART; SM00109; C1; 2.
DR   SMART; SM00239; C2; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1.
DR   SUPFAM; SSF57889; Cysteine-rich domain; 2.
DR   SUPFAM; SSF56112; Protein kinase-like (PK-like); 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS50004; C2; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS00479; ZF_DAG_PE_1; 2.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Angiogenesis; Apoptosis; ATP-binding; Calcium;
KW   Cell adhesion; Cell membrane; Cytoplasm; Kinase; Membrane; Metal-binding;
KW   Mitochondrion; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat; Serine/threonine-protein kinase; Transferase;
KW   Zinc; Zinc-finger.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000250|UniProtKB:P17252"
FT   CHAIN           2..672
FT                   /note="Protein kinase C alpha type"
FT                   /id="PRO_0000055682"
FT   DOMAIN          158..275
FT                   /note="C2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   DOMAIN          339..597
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          598..668
FT                   /note="AGC-kinase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00618"
FT   ZN_FING         36..86
FT                   /note="Phorbol-ester/DAG-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00226"
FT   ZN_FING         101..151
FT                   /note="Phorbol-ester/DAG-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00226"
FT   ACT_SITE        463
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         186
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:10562545"
FT   BINDING         187
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:10562545,
FT                   ECO:0000269|PubMed:19346474"
FT   BINDING         187
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|PubMed:10562545,
FT                   ECO:0000269|PubMed:19346474"
FT   BINDING         193
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|PubMed:10562545,
FT                   ECO:0000269|PubMed:19346474"
FT   BINDING         195
FT                   /ligand="a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-
FT                   inositol-4,5-bisphosphate)"
FT                   /ligand_id="ChEBI:CHEBI:58456"
FT                   /evidence="ECO:0000269|PubMed:19346474"
FT   BINDING         245
FT                   /ligand="a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-
FT                   inositol-4,5-bisphosphate)"
FT                   /ligand_id="ChEBI:CHEBI:58456"
FT                   /evidence="ECO:0000269|PubMed:19346474"
FT   BINDING         246
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:10562545,
FT                   ECO:0000269|PubMed:19346474"
FT   BINDING         246
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|PubMed:10562545,
FT                   ECO:0000269|PubMed:19346474"
FT   BINDING         247
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|PubMed:10562545,
FT                   ECO:0000269|PubMed:19346474"
FT   BINDING         248
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:10562545,
FT                   ECO:0000269|PubMed:19346474"
FT   BINDING         248
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|PubMed:10562545,
FT                   ECO:0000269|PubMed:19346474"
FT   BINDING         248
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000269|PubMed:10562545,
FT                   ECO:0000269|PubMed:19346474"
FT   BINDING         252
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000269|PubMed:10562545,
FT                   ECO:0000269|PubMed:19346474"
FT   BINDING         254
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:10562545,
FT                   ECO:0000269|PubMed:19346474"
FT   BINDING         254
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000269|PubMed:10562545,
FT                   ECO:0000269|PubMed:19346474"
FT   BINDING         345..353
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         368
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000250|UniProtKB:P17252"
FT   MOD_RES         10
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P17252"
FT   MOD_RES         226
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         319
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         494
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P04409"
FT   MOD_RES         495
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P04409"
FT   MOD_RES         497
FT                   /note="Phosphothreonine; by PDPK1"
FT                   /evidence="ECO:0000250|UniProtKB:P04409"
FT   MOD_RES         501
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P05771"
FT   MOD_RES         628
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P17252"
FT   MOD_RES         631
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:P68403, ECO:0000255"
FT   MOD_RES         638
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         651
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P17252"
FT   MOD_RES         657
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P05771"
FT   MOD_RES         658
FT                   /note="Phosphotyrosine; by SYK"
FT                   /evidence="ECO:0000250|UniProtKB:P20444"
FT   MUTAGEN         195
FT                   /note="Y->S: Reduced phosphatidylinositol 4,5-bisphosphate
FT                   recognition and impaired membrane docking. Loss of
FT                   phosphatidylinositol 4,5-bisphosphate-binding and strong
FT                   decrease of membrane docking; when associated with A-209;
FT                   A-211 and A-245."
FT                   /evidence="ECO:0000269|PubMed:19346474"
FT   MUTAGEN         209
FT                   /note="K->A: Loss of phosphatidylinositol 4,5-bisphosphate-
FT                   binding and strong decrease of membrane docking; when
FT                   associated with S-195; A-211 and A-245."
FT                   /evidence="ECO:0000269|PubMed:19346474"
FT   MUTAGEN         211
FT                   /note="K->A: Loss of phosphatidylinositol 4,5-bisphosphate-
FT                   binding and strong decrease of membrane docking; when
FT                   associated with S-195; A-209 and A-245."
FT                   /evidence="ECO:0000269|PubMed:19346474"
FT   MUTAGEN         245
FT                   /note="W->A: Reduced phosphatidylinositol 4,5-bisphosphate
FT                   recognition and impaired membrane docking. Loss of
FT                   phosphatidylinositol 4,5-bisphosphate-binding and strong
FT                   decrease of membrane docking; when associated with S-195;
FT                   A-209 and A-211."
FT                   /evidence="ECO:0000269|PubMed:19346474"
FT   STRAND          161..169
FT                   /evidence="ECO:0007829|PDB:3TWY"
FT   STRAND          172..182
FT                   /evidence="ECO:0007829|PDB:3TWY"
FT   STRAND          194..201
FT                   /evidence="ECO:0007829|PDB:3TWY"
FT   STRAND          222..230
FT                   /evidence="ECO:0007829|PDB:3TWY"
FT   HELIX           233..237
FT                   /evidence="ECO:0007829|PDB:3TWY"
FT   STRAND          239..246
FT                   /evidence="ECO:0007829|PDB:3TWY"
FT   STRAND          249..251
FT                   /evidence="ECO:0007829|PDB:3TWY"
FT   STRAND          254..262
FT                   /evidence="ECO:0007829|PDB:3TWY"
FT   HELIX           263..268
FT                   /evidence="ECO:0007829|PDB:3TWY"
FT   STRAND          271..276
FT                   /evidence="ECO:0007829|PDB:3TWY"
FT   HELIX           280..283
FT                   /evidence="ECO:0007829|PDB:3TWY"
FT   STRAND          288..290
FT                   /evidence="ECO:0007829|PDB:1DSY"
SQ   SEQUENCE   672 AA;  76792 MW;  94889E7339C17719 CRC64;
     MADVYPANDS TASQDVANRF ARKGALRQKN VHEVKDHKFI ARFFKQPTFC SHCTDFIWGF
     GKQGFQCQVC CFVVHKRCHE FVTFSCPGAD KGPDTDDPRS KHKFKIHTYG SPTFCDHCGS
     LLYGLIHQGM KCDTCDMNVH KQCVINVPSL CGMDHTEKRG RIYLKAEVTD EKLHVTVRDA
     KNLIPMDPNG LSDPYVKLKL IPDPKNESKQ KTKTIRSTLN PQWNESFTFK LKPSDKDRRL
     SVEIWDWDRT TRNDFMGSLS FGVSELMKMP ASGWYKLLNQ EEGEYYNVPI PEGDEEGNVE
     LRQKFEKAKL GPAGNKVISP SEDRKQPSNN LDRVKLTDFN FLMVLGKGSF GKVMLADRKG
     TEELYAIKIL KKDVVIQDDD VECTMVEKRV LALLDKPPFL TQLHSCFQTV DRLYFVMEYV
     NGGDLMYHIQ QVGKFKEPQA VFYAAEISIG LFFLHKRGII YRDLKLDNVM LDSEGHIKIA
     DFGMCKEHMM DGVTTRTFCG TPDYIAPEII AYQPYGKSVD WWAYGVLLYE MLAGQPPFDG
     EDEDELFQSI MEHNVSYPKS LSKEAVSICK GLMTKHPAKR LGCGPEGERD VREHAFFRRI
     DWEKLENREI QPPFKPKVCG KGAENFDKFF TRGQPVLTPP DQLVIANIDQ SDFEGFSYVN
     PQFVHPILQS AV
//
